Male hormonal contraceptives: a potentially patentable and profitable product

  title={Male hormonal contraceptives: a potentially patentable and profitable product},
  author={Paul B. Cornia and Bradley D Anawalt},
  journal={Expert Opinion on Therapeutic Patents},
  pages={1727 - 1737}
Although women have traditionally shouldered the responsibility of contraception, up to one-third of couples worldwide employ a male form of contraception (e.g., vasectomy or condoms). Vasectomy should be considered irreversible and long-term use of condoms is associated with a relatively high failure rate (pregnancy). Because many women are unable to use hormonal contraception and men want more contraceptive options, there is a need for a safe, effective, reversible and well-tolerated male… 
1 Citations

Long-acting testosterone undecanoate for parenteral testosterone therapy

Testosterone undecanoate is a new injectable testosterone preparation with a considerably better pharmacokinetic profile and Plasma testosterone levels with this preparation are almost always in the normal range.



Contraceptive efficacy of a depot progestin and androgen combination in men.

The first male contraceptive efficacy study using a prototype depot androgen/progestin combination demonstrates high contraceptive efficacy with satisfactory short-term safety and recovery of spermatogenesis.

A review of androgen-progestin regimens for male contraception.

It has been 40 years since the administration of steroids to women to prevent pregnancy was approved in many countries and finally the development of reversible hormonal contraceptives for men seems

Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception.

Although only 5 of 11 volunteers reached the target sperm counts (<3 million/mL), the study shows that a self-applicable hormonal male contraceptive could be developed.

Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations.

A multi-centre study to assess men's attitudes to proposed novel hormonal methods of contraception suggests that the emerging emphasis that men should have greater involvement in family planning will be substantiated when appropriate contraceptive methods become available.

Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.

Combination treatment with NETE showed suppression of spermatogenesis comparable with results using testosterone esters in combination with GnRH antagonists or cyproterone acetate, but had more favorable injection intervals and better efficacy.

Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.

It is concluded that the addition of a combined types I and II, 5alpha-reductase inhibitor or long-acting GnRH antagonist to a testosterone plus LNG regimen provides no additional suppression of gonadotropins or sperm concentration over an 8-wk treatment period.

Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.

It is concluded that with the dosages of Nal-Glu and T used in this study, the addition of GnRH antagonist to a high-dose T regimen does not increase the ability of T to suppress spermatogenesis in healthy men.

Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.

It is concluded that combination hormonal therapy with T plus a progestogen might offer a reversible male contraceptive approach with a more rapid onset of action and more reliable induction of both azoospermia and severe oligOSpermia than T alone.

An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.

This study documents the high efficacy of TU in combination with NET and confirms that this dose and mode of application is as effective as the previously reported regimen containing 1000 mg TU + 200 mg NETE im every 6 wk.